188PDImpact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). (23rd October 2018) - Untch, M; Jackisch, C; Schneeweiss, A; Schmatloch, S; Aktas, B; Denkert, C; Schem, C; Wiebringhaus, H; Kümmel, S; Rhiem, K; Warm, M; Fasching, P A; et al.